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Abstract
Purpose Despite superiority of tamsulosin–dutasteride combination therapy versus monotherapy for lower urinary tract 
symptoms due to benign prostatic hyperplasia (LUTS/BPH), patients at risk of disease progression are often initiated on 
α-blockers. This study evaluated the impact of initiating tamsulosin monotherapy prior to switching to tamsulosin–dutasteride 
combination therapy versus immediate combination therapy using a longitudinal model describing International Prostate 
Symptom Score (IPSS) trajectories in moderate/severe LUTS/BPH patients at risk of disease progression.
Methods Clinical trial simulations (CTS) were performed using data from 10,238 patients from Phase III/IV dutasteride 
trials. The effect of varying disease progression rates was explored by comparing profiles on- and off-treatment. CTS sce-
narios were investigated, including a reference (immediate combination therapy) and six alternative virtual treatment arms 
(delayed combination therapy of 1–24 months). Clinical response (≥ 25% IPSS reduction relative to baseline) was analysed 
using log-rank test. Differences in IPSS relative to baseline at various on-treatment time points were assessed by t tests.
Results Delayed combination therapy initiation led to significant (p < 0.01) decreases in clinical response. At month 48, 
clinical response rate was 79.7% versus 74.1%, 70.3% and 71.0% and IPSS was 6.3 versus 7.6, 8.1 and 8.0 (switchers from 
tamsulosin monotherapy after 6, 12 and 24 months, respectively) with immediate combination therapy. More patients tran-
sitioned from severe/moderate to mild severity scores by month 48.
Conclusions CTS allows systematic evaluation of immediate versus delayed combination therapy. Immediate response to 
α-blockers is not predictive of long-term symptom improvement. Observed IPSS differences between immediate and delayed 
combination therapy (6–24 months) are statistically significant.
Keywords Benign prostatic hyperplasia · Clinical trial simulation · Drug–disease modelling · Dutasteride · Lower urinary 
tract symptoms · Tamsulosin
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Introduction
The primary treatment goal for lower urinary tract symp-
toms associated with benign prostatic hyperplasia (LUTS/
BPH) is to reduce bothersome symptoms, with clinical 
management now focused on altering disease progression 
and preventing long-term complications such as surgery 
or acute urinary retention (AUR) [1–3]. Treatment guide-
lines for patients at risk of progression centre on two drug 
classes: 5α-reductase inhibitors (5-ARI) and α-blockers 
[4]. These recommendations are supported by data from 
large clinical studies, which indicate a significant reduc-
tion in risk of AUR and BPH-related surgery in patients 
treated with combination therapy [5, 6]. Additionally, the 
4-year Combination of Avodart and Tamsulosin (Com-
bAT) study showed that the dutasteride–tamsulosin com-
bination was more effective than tamsulosin monotherapy 
in reducing the relative risk of AUR, BPH-related surgery, 
and BPH clinical progression in men with moderate-to-
severe LUTS at increased risk of progression [7].
Following a LUTS/BPH diagnosis, patients are often 
treated initially with an α-blocker rather than combination 
therapy, including those at risk of disease progression. 
Whilst α-blockers may provide immediate symptomatic 
improvement, it is not possible to predict which patients 
will show sustained response over time, even if higher 
baseline symptoms [8] and/or larger prostates [9] are 
prognostic for deterioration of symptoms. No baseline or 
clinical factors have yet been identified that are sufficiently 
sensitive and specific to discriminate progression risk from 
long-term treatment response in individual patients [10]. 
Delaying combination therapy may reduce long-term ben-
efits due to the absence of a disease-modifying moiety in 
the initial treatment phase.
The implications of deviating from clinical guidelines 
about the use of combination therapy may have been over-
looked. Currently, treatment response is mostly assessed 
in clinical trials and clinical practice by the absolute 
change from baseline on the International Prostate Symp-
tom Score (IPSS) compared to placebo or active therapy. 
However, this does not provide insight into the effect of 
treatment on the rate of progression over time [11, 12]; 
rather, it describes the magnitude of change over a prede-
fined interval or time span. With respect to the profile of 
the IPSS measurements over time, any attempt to linearise 
or interpolate underlying progression rates from changes 
observed between consecutive visits may lead to inaccu-
rate estimates of disease progression [11].
Recently, we developed a longitudinal model using ran-
domised clinical trial data and follow-up studies includ-
ing placebo, tamsulosin, dutasteride and combination 
therapy, which enabled the characterisation of individual 
IPSS trajectories or profiles [13]. This model provides an 
opportunity to evaluate the impact of different interven-
tions, taking into account the role of other covariate fac-
tors known to affect response in patients with LUTS/BPH 
with moderate or severe symptoms.
Here, we use computer simulations in conjunction with 
baseline characteristics from patients participating in previ-
ous clinical trials to characterise the deterioration of symp-
toms associated with varying rates of disease progression 
and evaluate the long-term effects of different interventions 
based on individual IPSS trajectories. More specifically, we 
aim to assess the implications of delayed start of combina-
tion therapy in patients with moderate and severe symptoms.
Patients and methods
Initially, simulations were performed using the longitudinal 
model recently developed by D’Agate et al. [13] to illustrate 
the implications for treatment response when drugs with dis-
ease-modifying properties are used in patients with varying 
rates of disease progression. Further details of the model, 
including a description of the parameters and its implemen-
tation for the initial set of simulations are presented in the 
Supplemental Materials. Based on this preliminary evalu-
ation, baseline IPSS and disease progression rates interact 
with treatment effect, making it difficult to disentangle the 
contribution of each factor to the overall response at the end 
of a predefined interval, as assessed in most clinical trials. 
These findings support the use of clinical trial simulations 
(CTS) based on individual IPSS trajectories to assess the 
deterioration of symptoms associated with varying rates of 
disease progression and evaluate the effect of early versus 
delayed onset of combination therapy with the tamsulosin 
and dutasteride.
Different CTS scenarios were evaluated, taking into 
account demographic and clinical covariates known to affect 
response. The selected scenarios provide insight into the 
magnitude of treatment response differences following the 
initiation of combination therapy at different time points. 
An overview of the CTS steps, including the main protocol 
design characteristics, data input and output, is presented 
in Fig. 1a.
Data source
Demographic and clinical characteristics of the patient 
pool (N = 10,238) included in the CTS were obtained from 
six Phase III/IV clinical trials (ARIA3001, ARIA3002, 
ARI40002, CombAT, CONDUCT, ARIB3003). An over-
view of the patient population is shown in Supplementary 
Table S1. In CONDUCT, tamsulosin and dutasteride were 
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administered as a fixed-dose combination, while other 
studies administered treatment as separate dosage forms.
CTS scenarios
These evaluated the impact of immediate versus delayed 
start of combination therapy, and focused on the assess-
ment of treatment response defined as the proportion of 
subjects with a drop in IPSS ≥ 25% from baseline (i.e., 
the same endpoint in CombAT [14] and CONDUCT [15] 
studies included in this analysis) to signify a clinically 
meaningful improvement (CMI) at months 12, 24, 36 and 
48. Additionally, the relative difference in the proportion 
of patients who showed a CMI and transitioned between 
severity categories was evaluated at months 1, 3, 6, 12, 24 
and 48, as described below:
1. Severely symptomatic (IPSS 20–35) to mildly sympto-
matic (IPSS 1–7).
2. Moderately symptomatic (IPSS 8–19) to mildly symp-
tomatic (IPSS 1–7).
All CTS were performed assuming a protocol design 
aimed at mimicking clinical guidelines, in which non-
responders to α-blockers (patients who had a change in 
IPSS < 25% of baseline, i.e. who did not experience a CMI) 
switched to combination therapy at the selected time points. 
Given the large population sample size included in each sce-
nario, ten replicate trials were considered sufficient to cal-
culate the 90% confidence intervals (CIs) of the estimates. 
For clarity, graphical summaries were created using a single 
replicate trial. Full details of the protocol design character-
istics are shown in Table S2.
Results
Effect of immediate versus delayed start 
of combination therapy
Demographic characteristics of patients enrolled into each 
virtual treatment arm are summarised in Table S3. Fig-
ure 1b shows the mean IPSS change from baseline and 
predicted response rate for each treatment scenario. The 
different curves indicate that switching from tamsulosin 
monotherapy to combination therapy ≥ 6 months from the 
Fig. 1  a Schematic diagram of CTS based on the longitudinal model 
describing individual IPSS trajectories [13]. b Mean IPSS changes 
from baseline (left panels) and predicted response rate (% responders) 
(right panels) stratified by treatment scenario according to a parallel-
study design. From top to bottom, each panel depicts the predicted 
profiles for tamsulosin monotherapy (green dotted line), tamsulosin–
dutasteride combination therapy (red solid line), and treatment arm 
switching to combination therapy (blue dashed line) at 1, 3, 6, 12 and 
24 months. The lines depicting tamsulosin monotherapy and tamsu-
losin–dutasteride combination therapy are constant and represent 
these treatments being applied throughout 48  months. The dashed 
vertical lines indicate time of switch to combination therapy. Graphi-
cal summaries and statistical analysis refer to the results of a single 
replicate trial.  In these simulations, the placebo effect was assumed 
to occur only immediately after enrolment into the study. Placebo 
effect is a key component of the initial response and can last longer 
than 6 months, as assessed by its half-life. No studies included a pla-
cebo treatment arm for > 2 years, so it was not possible to establish 
whether inter-individual differences might allow for a longer placebo 
effect
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Fig. 1  (continued)
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start of treatment has a statistically significant effect on the 
proportion of responders at month 48.
The CTS scenarios confirm the anticipated impact of 
delaying combination therapy, with the observed differ-
ences in IPSS at month 48 appearing to be determined by 
the delay. The total number of subjects transitioning to 
combination therapy at the different visits is summarised 
in Table 1 (panels A and B), along with responder rate 
at end of the study and 90% CIs from ten trial replicates. 
From 6 months onwards, a significantly lower proportion 
of responders was observed in each virtual treatment arm 
relative to the combination therapy arm. These results are 
complemented by median estimates of the response rate 
for a single trial replicate (Table S4). Baseline character-
istics of the patients in each treatment arm are summarised 
to highlight that no other factor appears to predict the lack 
of response or explain which patients switch from tamsu-
losin monotherapy after 6, 12 or 24 months.
As summarised in Table  1 (panels C and D), the 
impact of the delayed start of combination treatment is 
also reflected in the total number of patients who tran-
sition from severe or moderate to mild IPSS categories 
over the 48-month period. In addition, the lower panel 
in Table 1 provides further evidence of the difference in 
magnitude of clinical improvement, assessed by percent-
age of responders per treatment arm with a decrease in 
IPSS ≥ 25%, ≥ 35%, ≥ 50% or ≥ 75% relative to baseline. 
These results indicate that a significant proportion of 
patients showed greater improvement in symptoms when 
combination therapy was started immediately.
Discussion
Meta-analyses have been used to compare different treat-
ment options. However, this technique allows scrutiny 
only of design factors that have been implemented, with-
out necessarily correcting for the effect of confounding 
factors which cannot be easily excluded. Moreover, they 
often focus on mean parameter estimates, yielding results 
that ignore underlying covariates that may modify the 
treatment effect. By contrast, the application of longitudi-
nal modelling and CTS at individual patient level allows 
investigation of a range of design characteristics on the 
power to detect treatment effects, without confounding 
or practical restrictions, prior to exposing patients to an 
experimental intervention [16, 17]. CTS can be performed 
not only to evaluate scenarios that have not been previ-
ously investigated in clinical trials, but also to explore 
hypothetical scenarios which cannot be implemented in 
real-life conditions. Indeed, the implementation of a pro-
spective, controlled study in which combination therapy 
is delayed may be ethically questionable, especially when 
guidelines recommend it in patients considered at risk for 
progression of BPH [4]. Here we have shown how this 
methodology can be used to explore design factors, such 
as delayed start of treatment, whilst disentangling it from 
other factors and interactions. Our analysis also provided 
an opportunity to assess the effect of disease progression, 
baseline covariates, and drug treatment on individual IPSS 
trajectories.
Treatment scenario Δ at 
1 year*
Δ at 
2 years*
Δ at 
3 years*
Δ at 
4 years*
Tamsulosin non-responders to CT at 1 month 1 1 1 1
Tamsulosin non-responders to CT at 3 months 1 1 1 1
Tamsulosin non-responders to CT at 6 months 0.168 1 1 0.704
Tamsulosin non-responders to CT at 12 months < 0.001 0.098 0.127 0.081
Tamsulosin non-responders to CT at 24 months < 0.001 < 0.001 0.022 0.038
    *Bonferroni corrected p-values for the change from baseline in mean IPSS of the different treatment 
scenarios, compared with reference (i.e. combinaon therapy (CT)). The change from baseline in mean IPSS
up to month 48 was a secondary endpoint in the clinical trial simulaon and as such, the study was not
powered to detect a pre-defined difference between treatment arms for this endpoint.  
IPSS, Internaonal Prostate Symptom Score. 
Fig. 1  (continued)
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Table 1  CTS results for each treatment arm based on a parallel-study design (ten trial replicates)
(A) Treatment duration Median number of patients transition-
ing to combination therapy (90% CI)
Start of treatment 0
01 month 489 (487, 493)
03 months 428 (413, 444)
06 months 284 (266, 306)
12 months 174 (163, 188)
24 months 157 (153, 173)
36 months  0
48 months  0
(B) Treatment arm Baseline  IPSSa Response rate (%)b IPSS at 48 months RespondersCT−  
Respondersx (%)
Combination therapy (CT) 17.1 [8–35] 79.7 (78.6, 81.2) 6.3 (6, 6.7)
Tamsulosin 17.3 [8–35] 65.5 (63.1, 68.1) 9.4 (8.8, 9.9)
Tamsulosin non-responders to CT at 1 month 17.1 [8–35] 79.5 (76.6, 81.4) 6.4 (6.2, 6.6) 0.2
Tamsulosin non-responders to CT at 3 months 17.2 [8–33] 78.1 (76.8, 81.0) 6.8 (6.4, 7.1) 1.6
Tamsulosin non-responders to CT at 6 months 16.9 [8–34] 74.1 (72.3, 75.5) 7.6 (7.2, 8.1) 5.6*
Tamsulosin non-responders to CT at 12 months 16.9 [8–35] 70.3 (67.3, 72.1) 8.1 (7.5, 8.6) 9.4*
Tamsulosin non-responders to CT at 24 months 17.0 [8–35] 71.0 (68.6, 72.1) 8.0 (7.8, 8.3) 8.7*
(C) Treatment arm Transition from moderate to mild at different study visits, cumulative % (range)
1 month 3 months 6 months 12 months 24 months 48 months
Combination therapy (CT) 4.6
(3.8, 5.2)
12.3
(11.2, 13.8)
22.3
(20.5, 23.3)
35.3
(34.4, 37.0)
44.7
(43.4, 46.4)
45.5
(44.2, 46.6)
Tamsulosin 3.0
(2.8, 3.42)
8.0
(6.5, 8.4)
13.6
(13.4, 14.6)
25.2
(23.4, 26.1)
32.9
(32.0, 34.8)
32
(31.0, 34.2)
Tamsulosin non-responders 
switching to CT at 1 month
4.1
(3.6, 5)
11.0
(10.6, 12.2)
21.6
(20.6, 23.0)
35.1
(34.4, 37.3)
43.3
(41.7, 45.8)
43
(41.4, 46.1)
Tamsulosin non-responders 
switching to CT at 3 months
3.9
(3.29, 4.4)
7.7
(6.3, 9.2)
17.3
(15.9, 21.0)
33.0
(31.1, 36.1)
41.6
(39.2, 44.6)
40.7
(38.3, 44.0)
Tamsulosin non-responders 
switching to CT at 6 months
3.2
(2.6, 3.5)
7.6
(7.0, 8.9)
14.4
(12.8, 15.8)
30.5
(29.1, 33.6)
40.7
(38.6, 42.6)
40.4
(37.9, 42.5)
Tamsulosin non-responders 
switching to CT at 12 months
3.6
(3.4, 4.2)
8.4
(7.4, 9.4)
14.8
(13.2, 15.9)
25.2
(23.0, 27.5)
37.9
(35.9, 40.9)
37.2
(35.7, 40.7)
Tamsulosin non-responders 
switching to CT at 24 months
3.3
(3.0, 4.2)
8.1
(7.0, 9.6)
14.7
(12.7, 16.4)
25.4
(23.1, 27.0)
34.3
(32.7, 35.0)
38.9
(37.0, 40.6)
(C) Treatment arm Transition from severe to mild at different study visits, cumulative % (range)
1 month 3 months 6 months 12 months 24 months 48 months
Combination therapy (CT) 0
(0, 0.1)
0.4
(0.2, 0.8)
2.2
(1.6, 2.8)
6.6
(4.8, 7.1)
12.8
(11.5, 13.4)
15.7
(13.8, 16.4)
Tamsulosin 0
(0, 0)
0.2
(0, 0.7)
1.1
(0.8, 1.5)
2.8
(2.6, 4.3)
6.8
(6.1, 9.0)
10.2
(9.0, 12.2)
Tamsulosin non-responders 
switching to CT at 1 month
0
(0, 0)
0.4
(0, 1.0)
1.8
(1.6, 2.9)
6.8
(5.3, 8.0)
13.3
(12.2, 14.8)
16.7
(15.2, 17.2)
Tamsulosin non-responders 
switching to CT at 3 months
0
(0, 0.4)
0.2
(0, 0.5)
1.3
(1.0, 2.3)
6.3
(5.0, 8.0)
13.6
(11.5, 15.4)
16.2
(14.6, 18.4)
Tamsulosin non-responders 
switching to CT at 6 months
0
(0, 0)
0.3
(0, 0.7)
0.9
(0.8, 1.9)
4.3
(3.0, 4.9)
9.3
(8.6, 10.7)
11.6
(10.8, 12.9)
Tamsulosin non-responders 
switching to CT at 12 months
0
(0, 0.2)
0.4
(0.2, 0.6)
1.0
(0.8, 1.2)
3.4
(2.2, 4.4)
9.4
(7.1, 10.1)
12.6
(9.7, 13.1)
Tamsulosin non-responders 
switching to CT at 24 months
0
(0, 0.1)
0.3
(0.2, 0.6)
1.2
(0.8, 1.7)
3.0
(2.6, 4.0)
7.1
(6.4, 8.2)
10.6
(9.8, 12.0)
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Effect of disease progression, baseline covariate 
factors and drug treatment on individual IPSS 
trajectories
Notwithstanding the body of evidence regarding the benefits 
of tamsulosin–dutasteride combination therapy, including 
greater and more durable improvement than with either 
monotherapy [14, 18, 19], little attention has been given to 
the impact of variable rates of disease progression on treat-
ment response or deterioration of symptoms, as measured by 
IPSS [10, 20, 21]. There are currently no reliable biomarkers 
that allow identification and prediction of a specific clini-
cal phenotype for disease progression in individual patients, 
although serum PSA has been explored in this capacity [8, 
9]. This is further compounded by limited understanding of 
the effects of specific comorbidities or other covariates on 
overall treatment response [22]. Our analysis suggests these 
limitations may partly be overcome by further characterisa-
tion of individual IPSS trajectories.
The introduction of IPSS as a tool for clinical practice 
and in research protocols was originally based on data from 
relatively short-term validation steps [23]. Among the avail-
able reports on the natural history of LUTS, long-term lon-
gitudinal follow-up studies have been restricted to changes 
in IPSS relative to baseline, making it difficult to distinguish 
the impact of multiple interacting factors on the deteriora-
tion of symptoms. Exploratory investigations have suggested 
that IPSS does not correlate with laboratory measures of 
urinary function at baseline (e.g., PV and PSA), but limita-
tions in the methodology employed indicate that this should 
not be taken as conclusive [24, 25]. In fact, the lack of such 
correlations has been often assigned to study design, inclu-
sion and exclusion criteria, and sample size. Nevertheless, 
baseline IPSS has been shown to predict the risk of progres-
sion in several prior clinical trials [6–8].
These apparently paradoxical findings may reflect the 
empirical nature of past research protocols, which assess or 
infer disease progression directly from the observed increase 
in IPSS over time, rather than based on a specific param-
eter that captures the underlying processes [26–28]. In this 
context, the initial simulations show the implications of the 
interaction between baseline covariates (e.g. IPSS) and vary-
ing rates of disease progression on individual trajectories 
(see Supplemental Materials). Although the possibility that 
patients with LUTS/BPH may show intrinsic differences 
in response to α-blockers and 5ARI cannot be excluded, it 
is clear from figures S1, S2 and S3 that the identification 
of inter-individual variation in progression rates only from 
Panel (A): overview of the patient population transitioning from tamsulosin to tamsulosin–dutasteride combination therapy due to non-
response to tamsulosin. Panel (B): primary endpoint, i.e. proportion of responders (response rate) and IPSS values at 48  months in patients 
responding to treatment. The difference in the proportion of responders in each virtual treatment arm relative to the combination therapy arm 
 [RespondersCT − Respondersx (%)] summarises the impact of immediate combination therapy. Panel (C): cumulative percentage of subjects 
switching from moderate or severe to mild symptom scores at each visit. Panel (D): Impact of immediate versus delayed start of tamsulosin–
dutasteride combination therapy on the magnitude of response, as assessed by the proportion of patients showing changes in IPSS ≥ 35%, ≥ 50% 
and ≥ 75% relative to baseline at month 48. The statistical significance of the differences between treatment arms for each response threshold is 
shown for a single replicate trial in Table S5 (see Supplemental Materials)
The results presented above refer to a CTS scenario including placebo effect only after the initial treatment phase. Placebo effect is an impor-
tant component of the initial response and can last more than 6 months, as assessed by its half-life. No studies included a placebo treatment 
arm for > 2 years, so it was not possible to establish whether inter-individual differences might allow for a longer placebo effect. Unless indi-
cated otherwise, values represent median (90% CIs) from ten trial replicates. Symptom severity: mild = IPSS 1–7, moderate = IPSS 8–19, and 
severe = IPSS ≥ 20
CI confidence interval, CTS clinical trial simulation, IPSS International Prostate Symptom Score
*Log rank test: p < 0.01
a Baseline IPSS [range] in each treatment arm
b percentage of responders (IPSS drop ≥ 25% relative to baseline) at 48 months
Table 1  (continued)
(D) IPSS improvement Percentage of patients (CI) showing improvement at month 48
≥ 25% ≥ 35% ≥ 50% ≥ 75%
Combination therapy (CT) 79.7 (78.6, 81.2) 73.1 (71.6, 74.8) 60.8 (59.0, 62.4) 31.2 (27.4, 32.6)
Tamsulosin 65.5 (63.0, 68.0) 57.4 (55.6, 60.0) 44.0 (42.5, 46.5) 17.0 (15.2, 18.6)
Tamsulosin non-responders switching to CT at 1 month 79.5 (76.5, 81.4) 71.1 (69.3, 74.7) 59.3 (56.6, 60.9) 29.1 (27.2, 29.9)
Tamsulosin non-responders switching to CT at 3 months 78.1 (76.8, 81.0) 71.0 (69.9, 73.9) 59.9 (56.3, 61.2) 28.4 (25.8, 31.3)
Tamsulosin non-responders switching to CT at 6 months 74.1 (72.3, 75.5) 65.8 (64.1, 68.6) 52.7 (50.6, 55.6) 22.4 (20.3, 24.2)
Tamsulosin non-responders switching to CT at 12 months 70.3 (67.2, 72.1) 62.4 (58.7, 64.6) 48.4 (45.1, 51.9) 20.2 (18.1, 24.4)
Tamsulosin non-responders switching to CT at 24 months 71.0 (68.5, 72.1) 63.2 (61.3, 65.0) 49.6 (46.9, 52.2) 19.4 (18.0, 21.0)
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baseline characteristics may be challenging. Further explo-
ration is required to identify whether baseline markers may 
explain some of this heterogeneity in symptom deterioration 
and consequently in treatment response.
Clinical trial simulations: impact of immediate 
versus delayed start of combination therapy
While the use of combination therapy in LUTS/BPH patients 
with moderate and severe symptoms at risk of disease pro-
gression is endorsed by international guidelines, this analy-
sis was performed taking into account prior evidence of the 
favourable benefit–risk profile of dutasteride–tamsulosin 
combination [29]. An early start of treatment with combina-
tion therapy should not alter the overall safety profile. How-
ever, the current results show that symptomatic treatment 
does not stop disease progression, and potentially reduces 
the benefits associated with the 5-ARI disease-modifying 
properties, if treatment is delayed for more than 6 months.
To address the key research question of this investigation, 
we have focused on the results of a parallel-study design, 
which reflects a typical clinical trial setting in which patients 
are randomised to different treatment arms, even though it 
does not fully capture the implications of delayed start of 
combination therapy for every single patient. In this regard, 
our results do not exclude the contribution of between-
patient variability on predicted treatment response. It is 
worth mentioning that baseline characteristics among tamsu-
losin non-responders do not differ significantly from patients 
on combination therapy raising questions as to whether base-
line demographics and clinical features may be sufficiently 
discriminative in determining treatment response. Yet, early 
administration of tamsulosin–dutasteride combination ther-
apy (i.e. < 6-month delay) not only results in a significantly 
greater responder rate at month 48 in men at risk of progres-
sion, but also leads to an increase in the fraction of patients 
transitioning to lower IPSS severity levels. More strikingly, 
early use of combination therapy results in a larger propor-
tion of patients having greater clinical improvement, i.e. 
changes in IPSS relative to baseline (Table 1, panels C and 
D). Early start of combination treatment allows ~ 10% more 
patients to benefit from symptomatic improvement.
The clinical relevance of differences in IPSS may be 
questioned without careful understanding of the approach 
used here. First, the definition of response based on a ≥ 25% 
reduction in IPSS relative to baseline allows for a standard-
ised measure across the entire population, irrespective of 
symptom severity at baseline, provided that the response 
strongly influences the relationship between the perception 
of improvement and the score improvement. This thresh-
old of ≥ 25% reduction in IPSS has been used as a study 
endpoint in various clinical trials included in this CTS [14, 
15]. Second, CTS were performed without residual noise to 
ensure accurate estimates of the effect of the different inter-
ventions. Residual noise reduces the sensitivity to detect a 
true treatment response.
Even though a few assumptions are required to assess 
treatment response when designing a standard clinical trial 
protocol or a virtual one, as in our case, our results highlight 
that immediate exposure to tamsulosin–dutasteride combi-
nation therapy can have a long-lasting impact on the indi-
vidual trajectories of a small, but clinically relevant fraction 
of patients (i.e. those who have a faster disease progression 
rate but cannot be identified at start of treatment). Consider-
ing the chronic nature of the disease, the effect of disease-
modifying properties cannot be compensated by sympto-
matic interventions over the longer term.
Undeniably, there are limitations in the work performed. 
First, it should be recognised that the population used for 
the development of the longitudinal model represents a sub-
group of the overall BPH patient population, and as such 
encompasses only subjects with moderate or severe symp-
toms at risk of progression. In addition, we have assumed 
that the placebo effect starts at the beginning of the trial and 
not when the therapy is switched at later time points. As the 
longitudinal model used for the simulations showed some 
bias in terms of the predicted trajectories severe patients 
with very high IPSS scores (i.e., upper 2.5th percentile), 
there is a chance of misclassification of non-responders. 
Last, we have not evaluated IPSS profiles beyond 48 months 
to ensure that simulation results could be supported by 
existing clinical data, i.e., the time span used in the analysis 
matches the duration of the longest clinical trial included in 
the development of the model.
Conclusions
We demonstrated how CTS can be used to describe indi-
vidual IPSS trajectories and explore the implications of 
immediate versus delayed start of tamsulosin–dutasteride 
combination therapy in men at risk of disease progression. 
Importantly, simulation scenarios showed higher overall 
response rates and significantly lower IPSS values following 
immediate combination therapy. Initiation of monotherapy 
in LUTS/BPH patients with moderate or severe symptoms, 
who are at risk of disease progression, may offer less advan-
tage; it appears to reduce the long-term benefit from early 
combination therapy. Patients eligible to initiate combina-
tion therapy may miss the symptomatic benefit over the long 
term, as shown by the significant difference in proportion 
of responders was observed in the treatment arms, when 
switching from tamsulosin occurs at 6 months or later.
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